|Bid||0.00 x 800|
|Ask||0.00 x 1300|
|Day's Range||6.98 - 7.37|
|52 Week Range||3.33 - 17.15|
|Beta (3Y Monthly)||2.97|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 6, 2019 - May 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.75|
Long term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow investors lose their hard-earned money. Anyone who held Lannett Company, Inc. (NYSE:LCI) for five years would...
PHILADELPHIA , March 27, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application ...
Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. For more information, visit the company's website at www.lannett.com.
Aerie (AERI) begins dosing in a phase II study on AR-1105 for treating patients with macular edema due to retinal vein occlusion.
Karyopharm's (KPTI) stock rises despite the FDA's decision to delay the verdict on the NDA filing of selinexor, which is developed for treating patients with relapsed-refractory multiple myeloma.
were rising Monday after the drugmaker announced it was entering an agreement with two other pharmaceutical players to sell a generic form of Adderall. and SunGen Pharma to be the exclusive distributor of a version of Adderall, an amphetamine tablet product. "We expect to launch this generic version of Adderall near term," said Tim Crew, CEO of Lannett.
Lannett Co. Inc. shares rose 3.1% in Monday premarket trading after the drug company announced an agreement with Elite Pharmaceuticals and SunGen Pharma to distribute a generic form of Adderall. Lannett Chief Executive Tim Crew said in a statement the drug will be available "in the near term." Adderall is used in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. Under the terms of the agreement, Lannett will provide sales, marketing and distribution support for the drug, receiving a share of the profits in exchange. Adderall, including generic versions, had an estimated market value of $361 million for the year ending January 2019. Lannett's stock has gained 58.5% for the year so far, while the S&P 500 index is up 9.4% for the period.
--Company Expects to Commence Marketing the Product Near Term-- PHILADELPHIA , March 11, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with ...
PHILADELPHIA , Feb. 26, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced its participation at two upcoming investor conferences. Schedule below: Raymond James 40th Annual Institutional ...
Announcement: Moody's announces completion of a periodic review of ratings of Lannett Company, Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Lannett Company, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Lannett Company, Inc. (NYSE: LCI ) reported solid second-quarter results Wednesday and raised its 2019 guidance. The pharma company is making good progress in preparing for the loss of levothyroxine with ...